178 related articles for article (PubMed ID: 30579570)
1. Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
Boudin L; Patient M; Tsitsi Nding Tsogou P; Roméo E; Bladé JS; de Jauréguiberry JP
Bull Cancer; 2019 Jan; 106(1):84-85. PubMed ID: 30579570
[No Abstract] [Full Text] [Related]
2. Definitive clearance of a chronic hepatitis E virus infection with ribavirin treatment.
Alric L; Bonnet D; Beynes-Rauzy O; Izopet J; Kamar N
Am J Gastroenterol; 2011 Aug; 106(8):1562-3. PubMed ID: 21811285
[No Abstract] [Full Text] [Related]
3. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
[No Abstract] [Full Text] [Related]
4. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
Molica S; Levato L; Mirabelli R; Tedeschi A; Lentini M
Leuk Lymphoma; 2018 Nov; 59(11):2734-2736. PubMed ID: 29465275
[No Abstract] [Full Text] [Related]
5. Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
[No Abstract] [Full Text] [Related]
6. Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
England JT; Leitch HA
Leuk Lymphoma; 2018 Mar; 59(3):752-754. PubMed ID: 28728450
[No Abstract] [Full Text] [Related]
7. Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients.
Marion O; Lhomme S; Del Bello A; Abravanel F; Esposito L; Hébral AL; Lavayssière L; Cointault O; Ribes D; Izopet J; Kamar N
J Hepatol; 2019 Jan; 70(1):206-209. PubMed ID: 30563687
[No Abstract] [Full Text] [Related]
8. Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia.
Gohil SH; Evans R; Harasser M; El-Kholy M; Paredes-Moscosso SR; Della Peruta M; Nathwani AC
Br J Haematol; 2019 Jul; 186(2):380-382. PubMed ID: 30957227
[No Abstract] [Full Text] [Related]
9. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
Cavazzini F; Lista E; Quaglia FM; Formigaro L; Cavallari M; Martinelli S; Rigolin GM; Foà R; Cuneo A
Leuk Lymphoma; 2016 Nov; 57(11):2685-8. PubMed ID: 26999572
[No Abstract] [Full Text] [Related]
10. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient.
Wang Y; Chen G; Pan Q; Zhao J
Gastroenterology; 2018 Mar; 154(4):1199-1201. PubMed ID: 29432746
[No Abstract] [Full Text] [Related]
11. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection.
Kamar N; Rostaing L; Abravanel F; Garrouste C; Lhomme S; Esposito L; Basse G; Cointault O; Ribes D; Nogier MB; Alric L; Peron JM; Izopet J
Gastroenterology; 2010 Nov; 139(5):1612-8. PubMed ID: 20708006
[TBL] [Abstract][Full Text] [Related]
12. Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for ribavirin?
Péron JM; Dalton H; Izopet J; Kamar N
J Hepatol; 2011 Jun; 54(6):1323-4; author reply 1324-5. PubMed ID: 21281681
[No Abstract] [Full Text] [Related]
13. Ibrutinib for Chronic Lymphocytic Leukemia with
Ahn IE; Tian X; Wiestner A
N Engl J Med; 2020 Jul; 383(5):498-500. PubMed ID: 32726539
[No Abstract] [Full Text] [Related]
14. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.
van der Valk M; Zaaijer HL; Kater AP; Schinkel J
J Hepatol; 2017 Jan; 66(1):242-243. PubMed ID: 27702641
[No Abstract] [Full Text] [Related]
15. Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Mazzucchelli M; Cairoli R; Montillo M
Future Oncol; 2018 Apr; 14(8):681-697. PubMed ID: 29243946
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
Tam CS; Kimber T; Seymour JF
Br J Haematol; 2017 Mar; 176(5):829-831. PubMed ID: 26915463
[No Abstract] [Full Text] [Related]
17. The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study.
von Felden J; Alric L; Pischke S; Aitken C; Schlabe S; Spengler U; Giordani MT; Schnitzler P; Bettinger D; Thimme R; Xhaard A; Binder M; Ayuk F; Lohse AW; Cornelissen JJ; de Man RA; Mallet V
J Hepatol; 2019 Sep; 71(3):465-472. PubMed ID: 31108159
[TBL] [Abstract][Full Text] [Related]
18. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
[TBL] [Abstract][Full Text] [Related]
19. Failure to respond to ribavirin despite elevated intra-erythrocyte zinc level in transplant-patients with chronic hepatitis E virus infection.
Marion O; Abravanel F; Izopet J; Kamar N
Transpl Infect Dis; 2019 Apr; 21(2):e13050. PubMed ID: 30663838
[No Abstract] [Full Text] [Related]
20. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
Christoforidou A; Kapsas G; Bezirgiannidou Z; Papamichos S; Kotsianidis Ι
Turk J Haematol; 2018 May; 35(2):147-149. PubMed ID: 29391330
[No Abstract] [Full Text] [Related]
[Next] [New Search]
